Question explored with the scientific record
Conversation so far
- 1 ozimpec side effects
- 2 What are the most common and serious side effects of semaglutide?
Answered on this page ↓
What are the most common and serious side effects of semaglutide?
Semaglutide's side effects are mostly stomach and gut trouble, and the serious ones are rare but real.
The common ones are nausea, vomiting, diarrhea, constipation, and stomach pain [4][7]. In a head-to-head trial, about 42 in 100 people on semaglutide had gut side effects versus 33 in 100 on a comparison drug [2]. Most are mild to moderate and ease as the body adjusts [4][1]. The worst of it clusters during dose escalation [5].
The serious ones are less common but documented: pancreatitis [6][7], gallbladder problems like cholecystitis [7], and a higher rate of diabetic eye complications in people who already had retinopathy, likely from blood sugar dropping too fast [8][9]. One case report describes a 48-year-old man who developed acute pancreatitis after starting semaglutide, with lipase over 4,900 [6]. That is one person, not a rate.
| Side effect | How often | Source |
|---|---|---|
| Gut symptoms (nausea, vomiting, diarrhea, constipation) | ~42 in 100 vs 33 in 100 comparator | [2] |
| Gut symptoms, obesity trials | ~15 in 100 | [3] |
| Discontinuation due to side effects | under 10 in 100 | [3] |
| Pancreatitis | case report only | [6] |
| Retinopathy worsening (pre-existing disease) | 3.0% vs 1.8% placebo | [8] |
The trials behind these numbers were largely manufacturer-run, and the longest safety follow-up in this evidence is about 40 months [5]. No record here tracks people past that. The retinopathy signal is real but concentrated in people who already had eye damage [8]. For most people without pre-existing retinopathy or pancreatitis history, the gut side effects are the main cost.
My call: for a person without prior pancreatitis or diabetic eye disease, the common side effects are manageable gut symptoms; the serious ones are uncommon but not negligible, and long-term data past a few years is missing. Confidence: moderate.
Sources used 9
-
Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study
This open-label, single-arm pilot study assesses the 24-week efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease (NAFLD) complicated by type 2 diabetes mellitus (T2DM), showing weight loss, improved liver enzymes and glycemic control, reduc…
DOI: 10.1002/jgh3.12780 -
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
This phase 3a trial demonstrated that once-weekly semaglutide 1.0 mg is superior to exenatide extended release 2.0 mg in improving glycemic control and reducing body weight in adults with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
DOI: 10.2337/dc17-0417 -
The Efficacy and Safety of Semaglutide-Based Medications for Long-Term Weight Loss and Cardiovascular Health
Systematic review of semaglutide-based medications for sustainable long-term weight loss and cardiovascular health, showing substantial weight loss (about 10–12 kg, BMI reductions ~2–3 units) and cardiovascular risk factor improvements across varied populations, with gastrointes…
DOI: 10.54393/pjhs.v6i4.2541 -
SEMAGLUTIDA COMO TRATAMENTO OFF-LABEL PARA OBESIDADE
Semaglutide is effective for weight loss in non-diabetic adults with obesity, with common but mostly mild-to-moderate gastrointestinal adverse effects, and should be used with professional follow-up.
DOI: 10.47820/recima21.v6i6.6494 -
Semaglutide (Wegovy)
The 2024 CDA-AMC resubmission review of semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with BMI ≥27 kg/m² and established cardiovascular disease is based primarily on the SELECT trial (N=17,604), a phase IIIb randomized, double-blind, placebo-controlled tria…
DOI: 10.51731/cjht.2025.1255 -
Semaglutide induced Pancreatitis
This case report discusses a 48-year-old male patient who developed acute pancreatitis after starting semaglutide, a glucagon-like peptide-1 receptor agonist, highlighting the potential risks associated with its use.
DOI: 10.36948/ijfmr.2024.v06i04.26238 -
Therapeutic Boon or Hidden Bane? Semaglutide for Weight Loss in Non-diabetics
A narrative review concludes that semaglutide achieves substantial weight loss and cardiovascular benefits in nondiabetic patients, but high cost, gastrointestinal and rare serious side effects, and misuse risks require comprehensive obesity-care strategies.
DOI: 10.29328/journal.jcmhs.1001080 -
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Across the SUSTAIN programme evaluating once-weekly semaglutide for type 2 diabetes, the analysis found no consistent increase in diabetic retinopathy events in most trials, but identified a higher risk of diabetic retinopathy complications (DRC) with semaglutide in high-risk pa…
DOI: 10.1111/dom.13172 -
Safety of injectable semaglutide for type 2 diabetes
A narrative safety review of injectable semaglutide for type 2 diabetes, synthesizing safety data from the SUSTAIN programme and related analyses, highlighting overall good safety with gastrointestinal effects, potential renoprotection, a signal for diabetic retinopathy risk lik…
DOI: 10.1080/14740338.2020.1772230